Solexa, Inc. (Nasdaq:SLXA) today announced two significant additions to its intellectual property (IP) portfolio. These advances relate to the use of reversible-terminator chemistry in DNA Sequencing-by-Synthesis (SBS) using either single molecules or clonal single molecules. The allowed claims combine with the company’s existing patent portfolio, which has been bolstered throughout the year by both internal developments and acquisition of key IP, to significantly enhance Solexa’s position in the field of SBS using amplified or non-amplified single molecule arrays.
